F. Loganzo

发表

The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents

P. Maslak, N. Altorki, G. Schwartz, 1995, International journal of cancer.

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

T. Fojo, F. Loganzo, M. Poruchynsky, 2004, Molecular cancer therapeutics.

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

T. Fojo, R. Andersen, J. Nieman, 2003, Cancer research.

Synthesis, molecular editing, and biological assessment of the potent cytotoxin leiodermatolide.

F. Loganzo, A. Maderna, A. Fürstner, 2014, Journal of the American Chemical Society.

Novel PIKK inhibitor antibody-drug conjugates: Synthesis and anti-tumor activity.

F. Loganzo, C. J. O’Donnell, E. Graziani, 2019, Bioorganic & medicinal chemistry letters.

Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.

F. Haluska, C. Shea, F. Loganzo, 1995, Cancer research.

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)

F. Loganzo, J. Lucas, E. Rosfjord, 2017, Molecular Cancer Therapeutics.

Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response

P. Loria, F. Loganzo, Aaron Y. Chang, 2021, The Journal of biological chemistry.

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

F. Loganzo, C. J. O’Donnell, J. Lucas, 2017, PloS one.

Tumor Cells Resistant to a Microtubule-Depolymerizing Hemiasterlin Analogue, HTI-286, Have Mutations in α- or β-Tubulin and Increased Microtubule Stability

E. Nogales, T. Fojo, D. Sackett, 2004 .

Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers.

A. Albino, F. Loganzo, D. Nanus, 1997, Urology.

Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells.

D. Scheinberg, A. Albino, F. Loganzo, 1997, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Mechanisms of Resistance to Antibody–Drug Conjugates

F. Loganzo, H. Gerber, M. Sung, 2016, Molecular Cancer Therapeutics.

Determination of Antibody-Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation.

F. Loganzo, Betsy S. Pierce, S. Puthenveetil, 2016, Bioconjugate chemistry.

Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia

F. Loganzo, C. J. O’Donnell, A. Maderna, 2020, Clinical Cancer Research.

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules

J. Snyder, J. Nettles, F. Loganzo, 2006, Molecular Cancer Therapeutics.

PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers

F. Loganzo, C. J. O’Donnell, J. Lucas, 2020, Molecular Cancer Therapeutics.

Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

F. Loganzo, H. Gerber, P. Sapra, 2016, Biochemical pharmacology.

Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism

S. C. K. Sukuru, F. Loganzo, C. J. O’Donnell, 2016, ACS medicinal chemistry letters.

Increases the Turnover of G-Protein ai-1’ and ari-Z-Subunit Messenger RNA in Sertoli Cells by a Mechanism That Is Independent of Protein Synthesis

F. Loganzo, P. Fletcher, 2001 .

MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

F. Loganzo, D. Sampath, C. Discafani, 2003, Molecular cancer therapeutics.

Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells.

P. Maslak, G. Schwartz, A. Albino, 1995, Journal of the National Cancer Institute.

Follicle-stimulating hormone increases guanine nucleotide-binding regulatory protein subunit alpha i-3 mRNA but decreases alpha i-1 and alpha i-2 mRNA in Sertoli cells.

F. Loganzo, P. Fletcher, 1992, Molecular endocrinology.

Catalytic activity of the SH2 domain of human pp60c-src; evidence from NMR, mass spectrometry, site-directed mutagenesis and kinetic studies for an inherent phosphatase activity.

D. G. Davis, D. Kassel, F. Loganzo, 1995, Biochemistry.

Suppressor Gene in Melanocytic Lesions Correlates with Invasive Stage of Tumor Progression1

F. Haluska, C. Shea, F. Loganzo, 1995 .

Depsides isolated from the Sri Lankan lichen Parmotrema sp. exhibit selective Plk1 inhibitory activity

David E. Williams, R. Andersen, F. Loganzo, 2011, Pharmaceutical biology.

Total syntheses and biological reassessment of lactimidomycin, isomigrastatin and congener glutarimide antibiotics.

F. Loganzo, A. Maderna, A. Fürstner, 2013, Chemistry.

Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.

Ramaswamy Nilakantan, Frank Loganzo, Fei Ye, 2004, Bioorganic & medicinal chemistry letters.

2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.

R. Nilakantan, F. Loganzo, A. Wissner, 2005, Journal of medicinal chemistry.

Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.

F. Loganzo, A. Wissner, M. B. Floyd, 2007, Bioorganic & medicinal chemistry.

D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors.

F. Loganzo, G. Krishnamurthy, L. Greenberger, 2004, Bioorganic & medicinal chemistry letters.

Destabilizing Agents: Peptides and Depsipeptides

F. Loganzo, L. Greenberger, 2008 .

Mutations and defective expression of the WAF1 p21 tumour‐suppressor gene in malignant melanomas

N. Hayward, A. Albino, F. Loganzo, 1995, Melanoma research.

Borrelidin B: isolation, biological activity, and implications for nitrile biosynthesis.

Roger G. Linington, F. Loganzo, Walter M. Bray, 2014, Journal of natural products.

Cytotoxic Spliceostatins from Burkholderia sp. and Their Semisynthetic Analogues.

F. Loganzo, C. J. O’Donnell, F. Koehn, 2014, Journal of natural products.

Synthesis and biological activity of analogues of the antimicrotubule agent N, β, β-trimethyl-L-phenylalanyl-N1-[(1S, 2E)-3-carboxy-1-isopropylbut-2-enyl]-N1, 3 -dimethyl-L-valinamide (HTI-286)

R. Williamson, F. Loganzo, C. Discafani, 2004 .

Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics.

G. Feuerstein, F. Loganzo, M. Burczynski, 2008, Biomarkers in medicine.

Anticancer Agents from Unique Natural Products Sources

M. K. Harper, T. Fojo, R. Andersen, 2003 .

Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-microtubule Agents

G. Parmigiani, C. Bettegowda, B. Vogelstein, 2004, Cancer biology & therapy.

Identification and Development of Vascular Disrupting Agents: Natural Products That Interfere with Tumor Growth

F. Loganzo, H. Gerber, C. May, 2013 .

Tumor Cells Chronically Treated with a Trastuzumab–Maytansinoid Antibody–Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments

M. Follettie, F. Loganzo, E. Melamud, 2015, Molecular Cancer Therapeutics.

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Z. Kan, F. Loganzo, J. Lucas, 2022, Molecular cancer therapeutics.

Discovery of Cytotoxic Dolastatin 10 Analogues with N-Terminal Modifications

Sai Chetan K. Sukuru, Frank Loganzo, Michael J. Shapiro, 2015 .

Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications.

Frank Loganzo, Carolyn A Leverett, Chakrapani Subramanyam, 2014, Journal of medicinal chemistry.

Establishing in vitro–in vivo correlation for antibody drug conjugate efficacy: a PK/PD modeling approach

Frank Loganzo, Tracey Clark, Dhaval K. Shah, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates.

F. Loganzo, C. J. O’Donnell, E. Graziani, 2016, Bioconjugate chemistry.

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates

F. Loganzo, C. J. O’Donnell, E. Graziani, 2017, The AAPS Journal.

Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.

M. Sudol, A. Albino, F. Loganzo, 1993, Oncogene.

Abstract 818: NG-HER2 ADC (PF-06804103) is superior to trastuzumab emtansine in a mouse 'avatar' head-to-head clinical trial

M. Kaplan, F. Loganzo, J. Lucas, 2018, Experimental and Molecular Therapeutics.

Follicle-stimulating hormone increases the turnover of G-protein alpha i-1- and alpha i-2-subunit messenger RNA in Sertoli cells by a mechanism that is independent of protein synthesis.

F. Loganzo, P. Fletcher, 1993, Molecular endocrinology.

Volumetric imaging of optically cleared and fluorescently labeled animal tissue (VIOLA) for quantifying the 3D biodistribution of nanoparticles at cellular resolution in tumor tissue.

S. Ram, F. Loganzo, M. Spilker, 2022, Journal of controlled release : official journal of the Controlled Release Society.

Hybrids of the hemiasterlin analogue taltobulin and the dolastatins are potent antimicrotubule agents.

F. Loganzo, A. Zask, S. Musto, 2005, Journal of the American Chemical Society.

Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.

Frank Loganzo, Tracey Clark, L. Nathan Tumey, 2016, Bioconjugate chemistry.

Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates.

F. Loganzo, C. J. O’Donnell, J. Lucas, 2018, Bioconjugate chemistry.

Two Photoaffinity Analogues of the Tripeptide, Hemiasterlin, Exclusively Label α-Tubulin

F. Loganzo, G. Krishnamurthy, A. Zask, 2005 .

Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy.

Frank Loganzo, Tracey Clark, Judy Lucas, 2014, Bioconjugate chemistry.

Mutation and expression of the low affinity neurotrophin receptor in human malignant melanoma

A. Albino, F. Loganzo, D. Nanus, 1996, Melanoma research.

Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.

J. Pandit, S. C. K. Sukuru, K. Parris, 2016, ACS medicinal chemistry letters.

Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.

E. Nogales, T. Fojo, D. Sackett, 2004, Biochemistry.

Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate

F. Loganzo, J. Lucas, E. Graziani, 2017, PloS one.

Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).

R. Williamson, F. Loganzo, C. Discafani, 2004, Journal of medicinal chemistry.

Total syntheses and biological reassessment of lactimidomycin, isomigrastatin and congener glutarimide antibiotics.

F. Loganzo, A. Maderna, A. Fürstner, 2013, Chemistry.

Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy.

F. Loganzo, J. Lucas, Tao He, 2014, Bioconjugate chemistry.

Determination of Antibody-Drug Conjugate Released Payload Species Using Directed in Vitro Assays and Mass Spectrometric Interrogation.

F. Loganzo, Betsy S. Pierce, S. Puthenveetil, 2016, Bioconjugate chemistry.

Abstract 4629: Tumor cells selected for resistance to an antibody-drug conjugate retain sensitivity to ADCs with modified linkers and payloads.

M. Follettie, F. Loganzo, C. J. O’Donnell, 2013 .